The Novosang project has received more than £12 million of funding to date.
This funding has enabled us to complete a proof of concept – demonstrating that red blood cells can be produced from pluripotent stem cells, meeting good manufacturing practice guidelines required for clinical use.
Our work has involved developing a process to enable scaling up production of red blood cells. We hope to translate our work into a first-in-man trial in healthy volunteers.
Further investment would now aid us in scaling up red blood cell production for full clinical trials, with a view to a larger-scale up to address demand for blood supplies.